Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes

Drug Metabolism and Disposition

Volumn 27, Issue 2, 1999, Pages 288-296

  Bourrié, Martine ^a   Meunier, Viviane ^a   Berger, Yves ^a   Fabre, Gérard ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CYTOCHROME P450 ISOENZYME; DILTIAZEM; IRBESARTAN; KETOCONAZOLE; NIFEDIPINE; TOLBUTAMIDE; TROLEANDOMYCIN; VERAPAMIL;

ADULT; AGED; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG OXIDATION; DRUG TRANSFORMATION; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER MICROSOME; MALE; MASS SPECTROMETRY; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; BIPHENYL COMPOUNDS; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; OXIDATION-REDUCTION; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TETRAZOLES;

EID: 0032935655     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE and Chenery RJ (1995) Ketoconazole and sulfaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
2. Birkett DJ, Mackenzie PI, Veroneze ME and Miners JO (1993) In vitro approaches can predict human drug metabolism. Trends Pharmacol Sci 14:292-294.
3. Bourrié M, Meunier V, Berger Y and Fabre G (1996) Cytochrome P450 isoform-inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
4. Butler MA, Iwasaki M, Guengerich FP and Kadlubar FF (1989) Human cytochrome P-450PA (P-4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86:7696-7700.
5. Cazaubon C, Gougat J, Bousquet F, Guiraudou P, Gayraud R, Lacour C, Roccon A, Galindo G, Barthelemy G, Gautret B, Bernhart C, Perrault P, Brelière JC, Le Fur G and Nisato D (1993) Pharmacological characterization of SR47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 265:826-834.
6. Chang TKH, Gonzalez FJ and Waxman DJ (1994) Evaluation of triaetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311:437-442.
7. Chauret N, Gauthier A and Nicoll-Griffith DA (1998) Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 26:1-4.
8. Chen L, Lee M, Hong J-Y, Huang W, Wang E and Yang CS (1994) Relationship between cytochrome P-450 2E1 and acetone catabolism in rats as studied with diallyldisulfide as an inhibitor. Biochem Pharmacol 48:2199-2205.
9. Cholerton S, Daly A and Idle JR (1992) The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 13:434-439.
10. Fabre G, Crevat-Pisano P, Dragna S, Covo J, Barra Y and Cano JP (1988a) Involvement of the macrolide antibiotic cytochrome P450-LM3c in the metabolism of midazolam by microsomal fractions prepared from rabbit liver. Biochem Pharmacol 37:1947-1953.
11. Fabre G, Julian B, Saint-Aubert B, Joyeux H and Berger Y (1993) Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos 21:978-985.
12. Fabre G, Rahmani R, Placidi M, Combalbert J, Covo J, Cano JP, Coulange C, Ducros M and Rampal M (1988b) Characterization of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers. Biochem Pharmacol 37:4389-4397.
13. Guengerich FP (1992) Characterization of human cytochrome P450 enzymes. FASEB J 6:745-748.
14. Guengerich FP, Kin D-H and Iwasaki M (1991) Role of human cytochrome P-450 IIE1 in the oxidation of several low molecular weight cancer suspects. Chem Res Toxicol 4:168-179.
15. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T and Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype of genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060.
16. Halpert JR, Guengerich FP, Bend JR and Correia MA (1994) Comparative issues in Toxicology; selective inhibitors of cytochromes P450. Toxicol Appl Pharmacol 125:163-175.
17. Krombach T, Mathys D, Gut J, Catin T and Meyers UA (1987) High performance liquid chromatography assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase and dextro-methorphan O-demethylase in microsomes and purified cytochrome P450 isoforms of human liver. Anal Biochem 162:24-32.
18. Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J and Maurel P (1992) Effects of imidazole derivatives on cytochrome P450 from human hepatocytes in primary culture. FASEB J 6:752-758.
19. Miners MO, Smith KJ, Robson RA, McManus ME, Veronese ME and Birkett DJ (1988) Tolbutamide hydroxylation by human liver microsomes: Kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol 37: 1137-1144.
20. Miners MO, Veronese ME and Birkett DJ (1994) In vitro approaches for the prediction of human drug metabolism, in Annual Reports in Medicinal Chemistry, (Bristol JA ed), vol. 29. pp 306-316, Academic Press, Inc.
21. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus, IC, Gotoh O, Okuda K and Neben DW (1993) The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 12:1-51.
22. Newton DJ, Wang RW and Lu AYH (1995) Cytochrome P450 inhibitors: Evaluation of specificity in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
23. Omura T and Sato R (1964) The carbon monoxide binding-pigment of liver microsomes: I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
24. Pelkonen O, Sotaniemi EA and Ahokas JT (1985) Coumarin 7-hydroxylase activity in human liver microsomes. Properties of the enzyme and inter-species comparison. Br J Clin Pharmacol 19:59-66.
25. Perrier L, Bourrié M, Marti E, Tronquet C, Massé D, Berger Y, Magdalou J and Fabre G (1994) In vitro N-glucuronidation of SR47436-BMS186295, a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions. J Pharm Exp Ther 271:91-99.
26. Pichard L, Gillet G, Fabre I, Dalet-Beluche I, Bonfils C, Thenot JP and Maurel P (1990) Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab Dispos 18:711-719.
27. Pollard HB, Menard R, Brandt HA, Pazoles CJ, Creutz CE and Ramu A (1978) Application of Bradford's protein assay to adrenal gland subcellular fractions. Anal Biochem 86:761-763.
28. Remmel RP and Burchell B (1993) Validation and use of cloned, expressed human drug-metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions. Biochem Pharmacol 46:559-566.
29. Renton KW (1985) Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochem Pharmacol 34:549-553.
30. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzales FJ and Trager WF (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions Chem Res Toxicol 5:54-59.
31. Rodrigues AD (1994) Use of in vitro human metabolism studies in drug development. An industrial perspective. Biochem Pharmacol 48:2147-2156.
32. Sesardic D, Boobis AR, Edwards RJ and Davies DS (1988) A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 26:363-372.
33. Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, De La Torre R and Davies DS (1990) Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man. Br J Clin Pharmacol 29:651-663.
34. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Inter-individual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
35. Tassaneeyakul W, Veronese ME, Birkett DJ, Gonzales FJ and Miners JO (1993) Validation of p-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem Pharmacol 46:1975-1981.
36. Tucker GT (1992) The rational selection of drug interaction studies; Implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther Toxicol 30:550-553.
37. Wrighton SA and Ring BJ (1994) Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine and nizatidine. Pharm Res 11:921-924.
38. Wrighton SA and Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21.